Charles River Laboratories International (NYSE:CRL) Earns “Hold” Rating from Argus

Argus reaffirmed their hold rating on shares of Charles River Laboratories International (NYSE:CRL) in a research report sent to investors on Friday morning, Marketbeat.com reports.

CRL has been the subject of a number of other reports. TD Cowen cut their price target on Charles River Laboratories International from $260.00 to $228.00 and set a hold rating for the company in a report on Monday, May 13th. StockNews.com downgraded shares of Charles River Laboratories International from a buy rating to a hold rating in a report on Friday, June 14th. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating on the stock in a report on Friday, May 10th. Mizuho assumed coverage on shares of Charles River Laboratories International in a research note on Friday, June 7th. They issued a neutral rating and a $235.00 target price for the company. Finally, TheStreet upgraded Charles River Laboratories International from a c+ rating to a b- rating in a research note on Friday, March 1st. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of Hold and a consensus price target of $254.50.

Charles River Laboratories International Stock Down 0.4 %

Shares of Charles River Laboratories International stock opened at $206.58 on Friday. Charles River Laboratories International has a 12-month low of $161.65 and a 12-month high of $275.00. The stock has a market capitalization of $10.64 billion, a P/E ratio of 24.30, a PEG ratio of 1.95 and a beta of 1.40. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The stock has a 50 day moving average price of $220.16 and a two-hundred day moving average price of $232.74.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Equities analysts expect that Charles River Laboratories International will post 11 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRL. VisionPoint Advisory Group LLC raised its stake in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares during the last quarter. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the 1st quarter worth approximately $41,000. Brown Brothers Harriman & Co. lifted its holdings in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares in the last quarter. Sunbelt Securities Inc. boosted its position in Charles River Laboratories International by 1,072.7% in the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after buying an additional 236 shares during the last quarter. Finally, Concord Wealth Partners increased its stake in shares of Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after buying an additional 203 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).